Replies to post #121502 on Biotech Values

[DewDiligence]

FCSC—While I believe azficel-T [laViv] has a better than 60% chance of approval, I now agree with Dew that it will have limited if any commercial value. The product had a bad reception the first go round in Europe…it's use will very likely be limited to nasolabial fold wrinkles, and I do not believe the effects are permanent. It was overhyped when first introduced in Europe and there was a big backlash. It is probably being overhyped this time as well.

Amen.

[Superfly15]

I think the odds are quite a bit higher, but I believe the same thing as you do...it is a wrinkle version of SOMX. That doesnt mean there isn't a trade in it though and I think it will pop pretty good if approved.